$7.48
1.91% yesterday
Nasdaq, Jun 28, 10:04 pm CET
ISIN
US12674W1099
Symbol
CABA
Sector
Industry

Cabaletta Bio Inc Share price

$7.48
-3.19 29.90% 1M
-15.85 67.94% 6M
-15.22 67.05% YTD
-5.87 43.97% 1Y
-0.60 7.43% 3Y
-2.52 25.20% 5Y
-2.52 25.20% 10Y
Nasdaq, Closing price Fri, Jun 28 2024
ISIN
US12674W1099
Symbol
CABA
Sector
Industry

Key figures

Market capitalization $361.11m
Enterprise Value $145.43m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.63
Turnover (TTM) Turnover $0.00
EBIT (operating result TTM) EBIT $-85.74m
Free cash flow (TTM) Free cash flow $-66.05m
Cash position $223.85m
EPS (TTM) EPS $-1.72
P/E ratio expected negative
Short interest 20.23%
Show more

Is Cabaletta Bio Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Cabaletta Bio Inc Share analysis

Unlock scores for free

Analyst opinions

11 Analysts have issued a Cabaletta Bio Inc forecast:

11x Buy
100%

Analyst opinions

11 Analysts have issued a Cabaletta Bio Inc forecast:

Buy
100%

Financial data from Cabaletta Bio Inc

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
- -
-
100%
- Direct costs 1.92 1.92
55% 55%
-
-1.92 -1.92
55% 55%
-
- Selling and administrative expenses 17 17
143% 143%
-
- Research and development costs 65 65
53% 53%
-
-84 -84
56% 56%
-
- Depreciation and amortization 1.92 1.92
55% 55%
-
EBIT (operating result) EBIT -86 -86
48% 48%
-
Net profit -77 -77
38% 38%
-

Figures in millions USD.

Don't miss a thing! We will send you all news about the Cabaletta Bio Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Cabaletta Bio Inc Share News

Positive
Seeking Alpha
about 14 hours ago
Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug with the same MoA as CABA-201, showing remarkable results with many patients experiencing full recoveries. Cabaletta stock has been sinking in 2024 however due to slow progress, manufacturing conc...
Neutral
GlobeNewsWire
15 days ago
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 –
Neutral
GlobeNewsWire
about one month ago
– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials –
More Cabaletta Bio Inc News

Company profile

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Head office United States
CEO Steven Nichtberger
Employees 103
Founded 2017
Website www.cabalettabio.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now